Nishan de Silva
Directeur/Membre du Conseil chez Alita Pharmaceuticals, Inc.
Fortune : 4 870 $ au 30/04/2024
Profil
Nishan M.
de Silva is currently a Director at Transposagen Biopharmaceuticals, Inc., Alita Pharmaceuticals, Inc., and Cartesian Therapeutics, Inc. He previously served as the Chief Executive Officer & Director at AFYX Therapeutics AS, and Radionetics Oncology, Inc. He was also the President, Chief Operating Officer & Director at Poseida Therapeutics, Inc. Additionally, he served as an Independent Director at Allos Therapeutics, Inc., Sophiris Bio, Inc., Talon Therapeutics, Inc., and Selecta Biosciences, Inc. He was a Principal at Warburg Pincus LLC, Sprout Group, and McKinsey & Co., Inc. Dr. de Silva holds an MBA from The Wharton School of the University of Pennsylvania, a doctorate from Perelman School of Medicine, and an undergraduate degree from Harvard College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,00% | 18/04/2024 | 233 ( 0,00% ) | 4 870 $ | 30/04/2024 |
Postes actifs de Nishan de Silva
| Sociétés | Poste | Début |
|---|---|---|
Alita Pharmaceuticals, Inc.
 Alita Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alita Pharmaceuticals, Inc. develops, manufactures and distributes urologic and female healthcare products. It offers product testing, research and development services. The company was founded by Carole S. Ben-Maimon and Warburg Pincus in September 2006 and is headquartered in Radnor, PA. | Directeur/Membre du Conseil | - |
Transposagen Biopharmaceuticals, Inc.
 Transposagen Biopharmaceuticals, Inc. BiotechnologyHealth Technology Transposagen Biopharmaceuticals, Inc. operates as a biotechnology company. Its products and services include piggyBac Reagents, cell engineering services and gene editing reagents & kits. The company was founded by Ostertag M. Eric in 2005 and is headquartered in Lexington, KY. | Directeur/Membre du Conseil | - |
Anciens postes connus de Nishan de Silva
| Sociétés | Poste | Fin |
|---|---|---|
Radionetics Oncology, Inc.
 Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Directeur Général | 03/01/2024 |
AFYX Therapeutics AS
 AFYX Therapeutics AS Miscellaneous Commercial ServicesCommercial Services AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark. | Directeur Général | 01/02/2022 |
CONNECT
 CONNECT Miscellaneous Commercial ServicesCommercial Services CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/11/2019 |
| POSEIDA THERAPEUTICS, INC. | President | 01/03/2018 |
| LIGAND PHARMACEUTICALS INCORPORATED | Directeur Financier/CFO | 21/05/2015 |
Formation de Nishan de Silva
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Perelman School of Medicine | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| POSEIDA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
Warburg Pincus LLC
 Warburg Pincus LLC Investment ManagersFinance Warburg Pincus LLC (Warburg Pincus) is a private equity subsidiary of Warburg Pincus & Company US LLC founded in 1966. The firm is headquartered in New York. | Finance |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Sophiris Bio, Inc.
 Sophiris Bio, Inc. Pharmaceuticals: MajorHealth Technology Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA. | Health Technology |
Selecta Biosciences, Inc.
 Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
Transposagen Biopharmaceuticals, Inc.
Transposagen Biopharmaceuticals, Inc. BiotechnologyHealth Technology Transposagen Biopharmaceuticals, Inc. operates as a biotechnology company. Its products and services include piggyBac Reagents, cell engineering services and gene editing reagents & kits. The company was founded by Ostertag M. Eric in 2005 and is headquartered in Lexington, KY. | Health Technology |
Sprout Group
 Sprout Group Investment ManagersFinance Sprout Group (Sprout) is venture capital subsidiary of Credit Suisse Private Equity LLC founded in 1969. The firm headquartered in New York. | Finance |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Talon Therapeutics, Inc.
 Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Health Technology |
Alita Pharmaceuticals, Inc.
Alita Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alita Pharmaceuticals, Inc. develops, manufactures and distributes urologic and female healthcare products. It offers product testing, research and development services. The company was founded by Carole S. Ben-Maimon and Warburg Pincus in September 2006 and is headquartered in Radnor, PA. | Health Technology |
CONNECT
CONNECT Miscellaneous Commercial ServicesCommercial Services CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA. | Commercial Services |
AFYX Therapeutics AS
AFYX Therapeutics AS Miscellaneous Commercial ServicesCommercial Services AFYX Therapeutics AS engages in research and development of pharmaceutical drugs. It develops a platform designed to deliver a pharmaceutical drug uni-directional to a mucosal surface. The company was founded in May 2014 and is headquartered in Virum, Denmark. | Commercial Services |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Health Technology |
